Deepcell
Aims to provide detailed genetic health information through ordinary blood sampling.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
* | N/A | $80.0m | Late VC |
| Total Funding | 000k | ||
Related Content
Deepcell is a biotechnology startup that operates in the field of cell analysis and sorting. The company's primary product is the REM-I platform, a cutting-edge technology that combines label-free imaging, deep learning, and gentle sorting to analyze and categorize cells based on their morphology, or shape and structure. This technology allows for a high-dimensional quantitative readout, meaning it can provide detailed and comprehensive data about individual cells.
Deepcell's technology is built on advanced microfluidics, a technique that manipulates tiny droplets of fluid in a controlled way, and artificial intelligence (AI). The AI component of the REM-I platform uses deep learning, a type of machine learning that mimics the workings of the human brain, to analyze and interpret the data gathered from the cell imaging. This combination of technologies allows for deep characterization of cells, providing valuable insights for researchers and scientists.
The company's clients are likely to be in the scientific and medical research fields, where detailed cell analysis is crucial. For example, pharmaceutical companies developing new drugs, or academic researchers studying diseases at a cellular level, could benefit from Deepcell's technology.
Deepcell's business model is likely based on selling or licensing its REM-I platform to these clients. The company may also generate revenue from providing data analytics services, using the powerful data gathered from its cell imaging technology to provide clients with detailed reports and insights.
In summary, Deepcell is a biotech startup that uses advanced technology to provide detailed cell analysis and sorting services. Its combination of microfluidics, AI, and data analytics makes it a leader in its field, and its REM-I platform is likely to be in high demand among scientific and medical researchers.
Keywords: Biotechnology, Cell Analysis, Cell Sorting, REM-I Platform, Microfluidics, Deep Learning, Artificial Intelligence, Data Analytics, Scientific Research, Medical Research.